First patient dosed with CUE-102 for recurrent glioblastoma multiforme (rGBM) at Dana-Farber Cancer Institute (DFCI) BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company developing a novel class of...Read more
Single-agent CD19 CAR-NK cell therapy achieved a complete response in third-line Waldenstrom macroglobulinemia (WM), a type of non-Hodgkin lymphoma Second patient maintains an ongoing complete response at six months with CD19 CAR-NK in combination with rituximab and a third WM...Read more
SOUTH SAN FRANCISCO, Calif., Aug. 13, 2025 (GLOBE NEWSWIRE) -- Aligos Therapeutics, Inc. (Nasdaq: ALGS, “Aligos”), a clinical stage biopharmaceutical company focused on improving patient outcomes through best-in-class therapies for liver and viral diseases, today announced that...Read more
PHOENIX, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a clinical-stage biotechnology company focused on regenerative and immune cellular therapies, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to...Read more
Cognition and FDA align on enriched population, study design, and endpoints PURCHASE, N.Y., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the Company or Cognition) (NASDAQ: CGTX), a clinical-stage company developing drugs that treat neurodegenerative disorders,...Read more
Approximately 500,000 U.S. Patients Are Diagnosed with Non-Cystic Fibrosis Bronchiectasis (NCFB), a Progressive Disease That Can Lead to Permanent Lung Damage BRINSUPRI 10 mg and 25 mg Doses Approved for the Treatment of NCFB BRINSUPRI, a First-in-Class DPP1 Inhibitor Targeting...Read more
Compass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MORE| Company | Change | Last Trade |
|---|---|---|
| Mettler-Toledo | 18.15 1.40 | $1,311.04 |
| Eli Lilly | 17.55 2.74 | $656.98 |
| Madrigal Pharmaceuticals | 14.92 4.16 | $373.92 |
| IDEXX Laboratories | 12.18 1.87 | $664.45 |
| Bio-Rad Laboratories | 9.92 3.61 | $284.68 |
| Chemed | 9.50 2.14 | $452.64 |
| Waters | 9.08 3.18 | $294.60 |
| Penumbra | 8.84 3.56 | $257.39 |
| UnitedHealth | 8.83 3.38 | $270.40 |
| Nutex Health | 7.88 8.20 | $104.00 |
| Medpace | 7.74 1.69 | $467.03 |
| Krystal Biotech | 7.44 5.18 | $151.06 |
| Thermo Fisher Scientific | 6.80 1.42 | $484.21 |
| argenx | 6.77 1.06 | $644.33 |
| United Therapeutics | 6.61 2.19 | $308.00 |
| ResMed | 6.44 2.27 | $289.73 |
| Humana | 6.19 2.25 | $281.13 |
| Vertex Pharmaceuticals | 6.01 1.55 | $393.78 |
| Company | Volume | Last Trade |
|---|---|---|
| X4 Pharmaceuticals | 73,542,216 | $3.07 |
| Cognition Therapeutics | 41,568,992 | $1.23 |
| Pfizer | 26,413,851 | $25.08 |
| Vor Bio | 26,359,354 | $2.00 |
| Incannex Healthcare | 24,867,656 | $0.41 |
| ImmunityBio | 24,695,074 | $2.84 |
| agilon health | 21,736,093 | $1.04 |
| Adaptimmune Therapeutics | 19,860,284 | $0.08 |
| Longeveron | 18,024,141 | $0.89 |
| Recursion | 17,723,808 | $5.67 |
| Tempus AI | 15,523,635 | $69.97 |
| Novo Nordisk | 15,209,177 | $50.64 |
| BioXcel Therapeutics | 13,636,353 | $5.62 |
| UnitedHealth | 13,399,450 | $270.40 |
| Geron | 13,310,526 | $1.42 |
| ProPhase Labs | 11,661,505 | $0.33 |
| PacBio | 11,256,269 | $1.33 |
| Absci | 10,610,127 | $3.21 |
| Iovance Biotherapeutics | 10,024,851 | $2.49 |
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
Recursion is a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery. Enabling its mission is the Recursion OS, a platform built across diverse technologies that continuously expands one of the world’s largest proprietary biological and chemical datasets...
CLICK TO LEARN MORE
Assertio is a leading commercial pharmaceutical company bringing differentiated products to patients. The Company has a robust portfolio of branded prescription products in three areas: neurology, hospital, and pain and inflammation. Assertio has grown through...
CLICK TO LEARN MORE
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
